中国临床药理学杂志2017，Vol.33Issue(12)：1098-1101,4.DOI:10.13699/j.cnki.1001-6821.2017.12.008
艾拉莫德片联合甲氨喋呤片治疗老年类风湿关节炎的临床研究
Clinical trial iguratimod combined with methotrexate on peripheral blood T lymphocyte and B lymphocyte in the treatment of elderly patients with rheumatoid arthritis
摘要
Abstract
Objective To investigate the clinical efficacy of iguratimod combined with methotrexate in elderly patients with rheumatoid arthritis (RA) and its effects on peripheral blood T lymphocyte and B lymphocyte.Methods A total of 120 elderly patients with RA were randomly divided into treatment group and control group,each group 60 cases.Control group was orally given methotrexate 10 mg,qd.Treatment group was orally given iguratimod 25 mg,twice a day on the basis of control group.All patients were treated for 3 months.After treatment,the clinical efficacy,improvement of joint symptoms,changes of laboratorytests and levels of peripheral blood T lymphocyte,B lymphocyte were compared in two groups.Results The clinical efficacy in treatment group was 93.34％ (56/60),had significant difference with that in control group,which was 80.00％ (48/60,P ＜ 0.05).The joint pain index,joint tenderness index and joint swollenness index were 6.85 ±3.02,4.21 ± 2.13,4.01 ± 1.03 in treatment group,had significant difference with those in control group,which were 10.16 ± 3.26,7.63 ± 3.16,6.15 ± 1.02 (P ＜ 0.05).After treatment,the levels of rheumatoid factor (RF),antistreptolyisn O antibody (ASO),C-reactive protein (CRP) in treatment group were (9.11 ± 3.02) U· mL-1,(112.26 ±9.54) U · mL-1,(3.46±0.07) g · L-1,had significant difference with those in control group,which were (15.31±5.24) U·mL-1,(143.15±9.25) U · mL-1,(7.40±1.02) g· L-1(P＜0.05).The levels of peripheral blood T lymphocyte CD3,CD4 and level of B lymphocyte in treatment group were (66.77 ± 5.42) ％,(38.31 ± 5.09) ％,(30.71 ± 4.79) ％,had significant difference with those in control group,which were (63.53 ±5.21) ％,(33.52 ±4.23) ％,(38.43 ±5.24)％ (P ＜0.05).While levels of CD8 in treatment and control groups were (27.32 ±4.48) ％,(27.54 ±4.21)％ (P ＞0.05).The adverse drug reactions in treatment group were gastrointestinal reaction,leucopenia,and abnormal liver function,the incidence of adverse drug reactions was 21.67％ (13/60).The adverse drug reactions in control group were gastrointestinal reaction,leucopenia,the incidence of adverse drug reactions was 18.33％ (11/60,P ＞ 0.05).Conclusion Iguratimod combined with methotrexate is effective in the treatment of elderly patients with RA,can significantly increase clinical efficacy,improve joint symptoms,indices of laboratory tests and regulate body immune function.关键词
艾拉莫德/甲氨蝶呤/类风湿关节炎/T淋巴细胞/B淋巴细胞Key words
iguratimod/methotrexate/rheumatoid arthritis/T lymphocyte/B lymphocyte分类
医药卫生引用本文复制引用
孟岩,李明远,罗德梅,张新玉,罗莉..艾拉莫德片联合甲氨喋呤片治疗老年类风湿关节炎的临床研究[J].中国临床药理学杂志,2017,33(12):1098-1101,4.基金项目
新疆医科大学第一附属医院2013年院内科研基金资助项目 （）
